Reported 2 days ago
Guggenheim initiated coverage on Summit Therapeutics Inc. (NASDAQ:SMMT) with a Buy rating and a price target of $40. Analyst Bradley Canino highlighted the stock's potential due to upcoming clinical trial results for their lung cancer drug, Ivonescimab. He noted that the stock has the potential for significant growth if their trials succeed, projecting a 34.72% upside in the next 12 months. Despite this optimism, he suggested that some AI stocks may offer better investment opportunities with lower risks.
Source: YAHOO